Silencing of gene expression by small interfering RNAs (siRNAs) is rapidly becoming a powerful tool for genetic analysis of mammalian cells. The use of DNA-based plasmid vectors to achieve transient and stable expression of siRNA has been developed to avoid the problems of double-stranded oligonucleotides transfection. These vectors direct the transcription of small hairpin RNAs (shRNAs) from a polymerase-III (H1 or U6)-RNA gene promoter. However, numerous disadvantages remain, including low transfection efficiency and difficulty in transfecting primary cells. To overcome some of these problems, the use of viral vectors for siRNA delivery has been described. Retroviral, adenoviral, adeno-associated and herpes viral shRNAs delivery systems have been successfully used to silence genes, in vitro and in vivo. The use of a herpes simplex virus type 1 (HSV-1)-based amplicon vector for siRNA delivery into mammalian cells, using human polyomavirus BK (BKV)-transformed cells as a model system is described. The results demonstrate the ability of amplicon vectors to inhibit the expression of BKV T-Ag and tumorigenicity of BKV-transformed cells. We show that the use of the amplicon vector is highly efficient for the delivery of siRNA molecules. The unique ability of these vectors to deliver multiple copies of siRNA may provide a useful tool in the development of novel anticancer therapy.
Post-transcriptional silencing by small interfering RNAs (siRNAs) has emerged as a powerful tool for genetic analyses in mammalian cells and has the potential to produce novel therapeutics. 1, 2 Unfortunately, oligonucleotides-mediated siRNA transfer suffers from several limitations, such as high cost, nonspecific toxicity transfection and transient suppression of gene expression. To overcome these problems, several groups have described alternative systems for siRNA expression within mammalian cells that rely on DNA vectors. 3 In general, these DNA vectors use an RNA polymerase III (Pol III) promoter to express short dsRNA in the form of an inverted repeat sequence containing a hairpin loop. Such small hairpin RNAs (shRNA) were shown to be efficiently processed into siRNAs inside the cells and achieved sequence-specific gene silencing.
The limited transfection efficiency and difficulty in transfecting primary cells has lead to the development of viral vector systems. Retroviral, lentiviral and adenoassociated (AAV) viral shRNAs delivery systems have been successfully used to silence genes, in vitro and in vivo but they possess several disadvantages among which are relatively restricted packaging capacity and inefficient large-scale production. [4] [5] [6] [7] [8] Furthermore, the random integration into the host genome can lead to unexpected activation or inhibition of endogenous gene expression. 9 The use of adenovirus-based vector for shRNA delivery, which can infect numerous cell types and can be obtained at high titer, is instead limited by episomal short-term expression of the transgene. 10 Owing to the limitations of the viral vectors so far tested, there is a need to develop improved vectors for siRNA delivery into mammalian cells.
Herpes simplex virus type 1 (HSV-1)-based vectors are currently being used for several gene therapy strategies. [11] [12] [13] These vectors possess three outstanding properties. First, the large capacity of the virus particle allows to package and efficiently deliver up to 150 kbp of DNA. Second, the virus genome contains more than 80 genes; approximately half of which, nonessential for replication, can be deleted without affecting virus production in cell culture. Third, HSV can infect a large number of cell types and is naturally neurotropic. There are two types of HSV-1 vector systems for gene transfer, termed amplicon and recombinant viruses. Recently, the use of HSV-1 amplicon vectors for siRNA delivery to glioma cells, able to suppress tumor growth in a nude mice model, has been described. 14 The possibility to use amplicon vectors for siRNA delivery into mammalian cells to inhibit syngenic tumor growth was investigated, utilizing as a target molecule the BK virus (BKV) T-antigen (T-Ag).
HSV-1 amplicon vectors represent the first 'gutted' DNA vector system and possess several unique features that distinguish them from other gene therapy vectors.
11,15 HSV-1 amplicons are bacterial plasmids containing two non-coding, genetic elements from HSV-1, an origin of DNA replication and a packaging/cleavage signal, which allow their replication and packaging as a 150 kb concatamer into HSV-1 particles. HSV-1 helper functions can be provided by replication-competentpackaging-defective HSV-1 genome, cloned as a bacterial artificial chromosome, to yield the amplicon particle (vector). Depending on the size of the recombinant amplicon plasmid, numerous copies of the transgene sequences (approximately from 10 to 25) are packaged in one vector particle, supporting high expression levels. As no virus proteins are encoded, amplicons are nearly non-toxic when packaged without contaminating helper virus. Moreover, they can infect most mammalian cell types and both dividing and non-dividing cells. Amplicons can be further engineered to allow the integration of their transgene into the cell genome, mediated by the rep protein of AAV.
BKV T-Ag has been selected as a model target protein to analyze the effect of amplicon-mediated siRNA delivery. BKV is a human polyomavirus with in vitro transforming activity for rodent 16 and human cells and it is oncogenic in hamsters, mice and rats. [17] [18] [19] In vitrotransformed rodent cells are immortalized and produce tumors in syngenic animals or nude mice. Association of BKV-DNA with human neoplasms has been reported, although its role in human tumorigenesis is still debated. 20 The early region of BKV genome encodes two proteins, large T (T-Ag) and small t (t-Ag) antigens. T-Ag behaves as an oncogene and is responsible for both the transforming and oncogenic activities. 21 The continuous expression of a functional T-Ag, detectable in all BKV-transformed cells, is necessary for the maintenance of transformation. One of these malignant BKV-transformed cell lines (pRPc cell line) has been established in our laboratory from normal BALB/c mouse fibroblasts and constitutively expresses T-Ag. 22 As demonstrated by studies on the highly homologous SV40 virus, 23 the stable suppression of T-Ag expression in BKV-transformed cell lines should suppress the in vitro and in vivo Two siRNAs, namely siRNA 1390 and 714, were identified that abolish T-Ag expression and siRNA 1390 was chosen for this study. 24 To express stable 1390 siRNA, the vector psiBKVT-1390-hHGFPzeoG2 ( Figure  1a) was constructed, encoding the shRNA against T-Ag (shBKVT-1390) under the control of H1 RNA promoter. Twenty-four hours after transfection of psiBKVT-1390-hHGFPzeoG2 into pRPc cells, immunofluorescence analysis revealed that green fluorescent protein (GFP)-positive cells had a simultaneous marked reduction of the nuclear rhodamine fluorescence for T-Ag, demonstrating that shBKVT-1390 was active in suppressing T-Ag expression (Figure 1b) . These results provided the basis for further experiments using an amplicon vector as delivery system.
As cellular effect of mRNA knockdown requires high gene transfer efficiency, which cannot be achieved by plasmid transfection strategies, an amplicon vector able to efficiently express siRNA molecules was developed. Using the helper-free amplicon packaging system developed by Saeki et al., 25 we constructed an amplicon plasmid, pA-shBKVT, that expresses shBKVT-1390 under the control of the H1 RNA promoter (Figure 2a, left) . The pA-shBKVT amplicon vector contains the GFP gene under the control of HSV-ICP4 immediate early promoter (IE4pr). Transduction of pRPc cells with the pA-shBKVT amplicon vector, at a multiplicity of transduction (MOT) of 1 (determined in the human glioblastoma cell line G16.9), resulted in poor expression of GFP (Figure 2a, right) . This was probably due to the lack of viral or cellular transactivating functions in the pRPc cells, a limitation in establishing the efficiency of the transgene delivery. To improve this system, we inserted HSV-1 amplicon vector for siRNA transfer S Sabbioni et al into pA-shBKVT vector a second copy of the GFP gene under the control of SV40 enhancer-hEF1/HTLV promoter (Figure 2b, left) . Transduction of pRPc cells with the packaged pA-shBKVT-GFP amplicon vector resulted in about seven-fold detection of GFP expression gene (Figure 2b , right side). pRPc cells were transduced with the vector at 1 transducing unit (TU)/cell to test the functionality of the pA-shBKVT-GFP amplicon vector. After 2 days, the cells were stained with an anti-large T-Ag antibody and examined with a fluorescence microscope to detect both the large T-Ag (red) and the GFP (green)-expressing cells. The results in Figure 3a show that T-Ag expression was suppressed or markedly reduced in GFP-positive cells, demonstrating that shBKVT was active in 'knocking down' the T-Ag. A Western blotting assay was performed to confirm the reduction of the T-Ag protein and to assess whether the reduction was a specific effect of the siRNA. The pAshControl amplicon vector, expressing a scrambled sequence, was used as control. pRPc cells were transduced with the pA-shBKVT-GFP amplicon vector or with pA-shControl amplicon vector at 5 TU/cell and after 2 days the cells were collected and Western blotting was performed to detect the T-Ag protein. The results show that T-Ag expression was inhibited specifically by the pA-shBKVT-GFP amplicon vector, whereas the pAshControl amplicon vector has no effect on the expression of the protein (Figure 3b) .
In vitro or in vivo assays were performed to assess the growth capability of pRPc-transduced cells. In in vitro experiments, pRPc cells were either non-transduced, transduced with the pA-shBKVT-GFP amplicon or with the empty control amplicon pA-EUA, derived from the pA-SF1 amplicon plasmid. 26 The cell number was determined at 24, 48 and 72 h post-transduction, using a MOT ranging from 0.5 to 5. In comparison with control amplicon or non-transduced cells, the cellular growth rate was reduced in a dose-dependent manner in cells infected by pA-shBKVT-GFP amplicon vector ( Figure  4a) . The difference between the pA-shBKVT-GFP-and the pA-EUA-transduced cells at MOT 5 was statistically different, using the Students t-test (P ¼ 0.003). These data demonstrate a direct association between the level of siRNA expression and T-Ag 'knock down'. . Immunofluorescence was performed as described in Figure 1. 4 0 ,6-diamidino-2-phenylindole dihydrochloride counterstaining was used to visualize the nuclei. As shown by the expression of the GFP reporter gene, the cells were efficiently transduced and expression of nuclear T-Ag was suppressed or markedly reduced. (b) Forty-eight hours after transduction of pRPc cells with the pA-shBKVT-GFP amplicon (pA-shBKVT-GFP) at 5 TU/cell, the expression of T-Ag was evaluated by Western blotting. Controls included non-transduced pRPc cells (No virus) or transduced with the pA-shControl amplicon vector expressing a scrambled sequence (pA-shControl) (5 TU/cell). Detection of beta-actin served as an internal loading control. Anti-BK virus large T-Ag monoclonal antibody was from Chemicon International (Temecula, CA, USA). Anti beta-actin antibody was from SigmaAldrich (St Louis, MO, USA). The results show that the 87 kDa T-Ag protein expression was specifically inhibited by the pA-shBKVT-GFP amplicon vector, whereas the pA-shControl amplicon vector had no effect on the expression of the protein.
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As expression of BKV T-Ag is needed to maintain the oncogenic phenotype of BKV-transformed cells, we then investigated if pA-shBKVT-GFP amplicon vector could suppress in vivo tumorigenicity of pRPc cells. Twentyfour hours after transductions of pRPc cells with pAshBKVT-GFP at 5 TU/cell, 2 Â 10 5 cells were subcutaneously injected into eight newborn syngenic BALB/c mice. Control groups included either non-transduced (four mice), transduced with pA-EUA control amplicon (four mice) or transduced with pA-shControl amplicon vector (four mice). The latency period for the appearance of a detectable nodule was about 8 days in the untreated, pA-EUA or pA-shControl control groups. In the pAshBKVT-GFP amplicon-treated animals, tumor growth was undetectable even at day 31 after implantation, whereas tumors originating from pA-EUA-and the pAshControl-treated cells were still growing (Figure 4b ).
These data support a tumor suppression capability of pA-shBKVT-GFP in the transduced pRPc cells.
These results confirm that HSV-1 amplicon vectors are efficient tools for the delivery of siRNA into mammalian cells. As they are easy to construct, they allow the rapid evaluation of numerous siRNA molecules for targeting specific genes, including oncogenes. As amplicon vectors can generate genomes containing multiple copies of the insert, they appear to be particularly attractive as they may favor expression of siRNA at high level, when compared to the other viral vectors so amplifying the biological effect. The possibility to amplify the transgene expression may allow the dose of the therapeutic vector to be lowered, minimizing a possible intrinsic toxic effect, as reported in the literature for other vectors. This study shows that amplicon-mediated delivery of anti-BKVT siRNA can inhibit T-Ag expression and growth of 4 pRPc cells were seeded in a 1 cm diameter multi-well plate. Twenty-four hours later, cells were either non-transduced or transduced, in triplicate, with pA-shBKVT-GFP amplicon at 0.5, 1, 2, 5 TU/cell or with the pA-EUA empty control amplicon at 5 TU/cell. 26 The number of living cells was determined in triplicate samples at 24, 48 and 72 h after transduction by Trypan blue staining. Compared to controls, the growth rate of pRPc cells was markedly reduced by the pA-shBKVT-GFP amplicon vector in a dose-dependent manner. The difference between the pA-shBKVT-GFP-and the pA-EUA-transduced cells at MOT 5 was statistically different, as evaluated by t-test (*P ¼ 0.003). (b) In vivo growth kinetics. Twenty-four hours after birth, pathogen-free BALB/c mice (Charles River Laboratories, Calco, Lecco, Italy) were subcutaneously injected in the back with 2 Â 10 5 pRPc cells, either non-transduced or transduced with 5 TU/cell of pA-shBKVT-GFP, pA-EUA, pA-shControl amplicon vectors. Tumor growth was monitored every 2 days for 31 days by measuring tumor size with a calliper. Vertical scale: tumor size in mm 3 ; horizontal scale: time intervals in days. In the pA-shBKVT-GFP amplicon-treated animals, the tumor growth was undetectable even at day 31 after implantation, whereas tumors originating from pA-EUA and the pA-shControl-treated cells continued to grow. This research was conducted in line with internal policies regarding animal use. *Significant reduction (Po0.05).
HSV-1 amplicon vector for siRNA transfer S Sabbioni et al BKV-induced tumors, supporting their use as therapeutic anticancer molecules.
One major difficulty in the advancement of cancer gene therapy technology is associated with the production of vector systems able to transduce only neoplastic cells. A versatile method has been designed for targeting HSV-1-based amplicon to unique cell surface receptors. A recombinant HSV-1 vector has recently been constructed to specifically target human malignant glioma cells. 27, 28 On this basis, amplicons may represent novel siRNA delivery tools, which could potentially be used for the treatment of human-specific tumors.
